Pharmaceuticals

Next Generation Complement Therapeutics Market Size Forecast: Revenue and CAGR by 2029

November 20, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Market Value Is The Next Generation Complement Therapeutics Industry Expected To Reach By 2029, Starting From 2025 Levels?

The next generation complement therapeutics market has experienced significant expansion recently. It is projected to increase from $6.36 billion in 2024 to $7.38 billion in 2025, achieving a compound annual growth rate (CAGR) of 16.1%. The historical drivers for this growth include the rising acceptance of companion diagnostics, an uptick in personalized treatment strategies, the proliferation of telemedicine and digital health platforms, a stronger emphasis on rare and orphan diseases, and the augmented use of AI and machine learning in drug discovery.

The next generation of complement therapeutics market is projected to experience substantial expansion over the coming years. By 2029, its valuation is anticipated to reach $13.24 billion, demonstrating a compound annual growth rate (CAGR) of 15.7%. This forecasted growth is primarily driven by factors such as increased investments from venture capital and private equity firms, the worldwide expansion of clinical trials, a greater reliance on real-world evidence (RWE), a rise in neurodegenerative disease diagnoses, and the introduction of microbiome-based therapeutic approaches. Key developments expected during this period involve the incorporation of digital biomarkers into clinical trials, the widespread adoption of CRISPR and gene editing technologies, the creation of multi-specific antibodies, the use of digital twins for simulating patients and delivering precise care, and the application of 3D bioprinting for customized drug evaluation and implants.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27360&type=smp

What Are The Drivers Pushing New Developments In The Next Generation Complement Therapeutics Market?

The rise in prevalence of chronic diseases is anticipated to fuel the expansion of the next-generation complement therapeutics market moving forward. A chronic disease refers to a persistent health condition that necessitates continuous management to alleviate symptoms and enhance the quality of life. The increase in chronic diseases stems from sedentary lifestyles, which restrict physical activity, disrupt metabolic processes, and heighten long-term health dangers. Next-generation complement therapeutics address chronic diseases by accurately targeting and regulating an overactive complement system, thereby diminishing inflammation and averting tissue damage. For example, in January 2022, the American Cancer Society, a US-based non-profit organization focused on cancer awareness, projected that the US would see approximately 1.9 million new cancer cases and 609,360 cancer-related fatalities, amounting to roughly 1,670 deaths each day. Consequently, the growing prevalence of chronic diseases is powering the expansion of the next-generation complement therapeutics market.

What Are The Primary Types Of Segments Analyzed In The Next Generation Complement Therapeutics Market?

The next generation complement therapeutics market covered in this report is segmented

1) By Type Of Therapy: Monotherapy, Adjunctive Therapy

2) By Molecule Type: Biologic, Small Molecule

3) By Route Of Administration: Intravenous, Oral, Intravitreal, Subcutaneous

4) By Indication: Paroxysmal Nocturnal Hemoglobinuria, Geographic Atrophy (GA) Secondary To Age-Related Macular Degeneration, Generalized Myasthenia Gravis, Atypical Hemolytic Uremic Syndrome, Other Indications

5) By Therapeutic Area: Hematology, Ophthalmology, Neurology, Immunology Or Rheumatology, Other Therapeutic Areas

Subsegments:

1) By Monotherapy: C3 Inhibitors, C5 Inhibitors, Factor D Inhibitors, Factor B Inhibitors, C1 Inhibitors, MASP-2 Inhibitors

2) By Adjunctive Therapy: Combination With Immunosuppressants, Combination With Steroids, Combination With Plasma Exchange, Combination With Biologics, Combination With Chemotherapeutics, Combination With Anticoagulants

What Long-Term Trends Will Shape The Future Growth Of The Next Generation Complement Therapeutics Industry?

Leading companies in the next-generation complement therapeutics market are concentrating on developing advanced treatments, such as novel anti-C5 recycling monoclonal antibodies, to offer more effective and less frequently administered options for complement-mediated disorders. An anti-C5 recycling monoclonal antibody is a bioengineered molecule designed to target and inhibit complement protein C5, thereby suppressing inflammation, while its recycling mechanism within the body enhances its half-life and overall therapeutic impact. For instance, in December 2022, Roche AG, a pharmaceutical company from Switzerland, announced promising Phase III data from its COMMODORE 3 study, revealing that crovalimab, a novel anti-C5 antibody, is both effective and well-tolerated in people with PNH in China. This treatment successfully met its primary goals of reducing the need for blood transfusions and controlling hemolysis. Crovalimab, designed for subcutaneous use every four weeks, provides a convenient, self-administered alternative to existing therapies. With Priority Review status granted by Chinese regulators, it is anticipated to soon become a valuable treatment option for PNH, particularly where access to C5 inhibitors is currently very limited.

Who Are The Primary Competitors In The Global Next Generation Complement Therapeutics Market?

Major companies operating in the next generation complement therapeutics market are AstraZeneca PLC, Novartis AG, Amgen Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Vertex Pharmaceuticals, Genentech Inc., Genmab A/S, Mallinckrodt Pharmaceuticals Ltd., Alnylam Pharmaceuticals Inc., Apellis Pharmaceuticals Inc., Omeros Corporation, CANbridge Pharmaceuticals Inc., Alexion Pharmaceuticals Inc., Molecular Partners AG, NovelMed Therapeutics Inc., InflaRx GmbH, Amyndas Pharmaceuticals S.A., Kira Pharmaceuticals Inc., ReAlta Life Sciences Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/next-generation-complement-therapeutics-global-market-report

Which Geographies Are Emerging As Strong Markets For The Next Generation Complement Therapeutics Industry?

North America was the largest region in the next generation complement therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next generation complement therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Next Generation Complement Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/customise?id=27360&type=smp

Browse Through More Reports Similar to the Global Next Generation Complement Therapeutics Market 2025, By The Business Research Company

Payment Gateway Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/payment-gateway-global-market-report

Payment Processor Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/payment-processor-global-market-report

Quantum Technology Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/quantum-technology-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795